Dr. Agarwal's Health Care Limited IPO

Established in 2010, Dr. Agarwal's Health Care Limited delivers a wide-ranging service of ophthalmic solutions, including cataract and refractive surgery, consultation and diagnosis, and non-surgical treatments, sales of optical goods, contact lenses, accessories, and pharmaceutical drugs related to eyes.

As of September 30, 2024, the company had 737 doctors treating patients in its facilities. During the same period, the company treated 2.13 million patients and performed 220,523 surgeries. For the six months ended September 30, 2024, they treated 1.15 million patients and performed 140,787 surgeries.

The Services offered by the company are:
Cataract surgeries; Provide cataract surgical services in its own facilities, which include small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments;
Refractive surgeries: These are surgeries used to correct the refractive errors of the eyes, helping a person decrease their dependence on eyeglasses or contact lenses. The major categories are LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).
Other surgeries: Provide a number of other surgical interventions for ocular diseases, like surgical retinal interventions, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries to treat glaucoma and pterygium.

By September 30, 2024, the company's Indian network includes 28 hubs (Tertiary Facilities, three COEs included) and 165 spokes (53 Primary and 112 Secondary Facilities).As on September 30, 2024, the Company has operations in India across 117 metro and non-metro cities in 14 states and four union territories through 193 Facilities.